Professional Documents
Culture Documents
Von Willebrand's Disease
Von Willebrand's Disease
Review Article
V
on Willebrand’s disease is an inherited bleeding disorder From the Department of Hematology,
characterized by defective platelet adhesion and aggregation. The disorder Erasmus University Medical Center, Rotter-
dam (F.W.G.L.), and the Department of
was first described in 1926 by Erik von Willebrand, who recognized that it Thrombosis and Hemostasis, Leiden Uni-
differed from hemophilia and named it “hereditary pseudohemophilia.”1 The fac- versity Medical Center, Leiden (J.C.J.E.)
tor in plasma that corrects the disease was not identified until many years later — both in the Netherlands. Address re-
print requests to Dr. Leebeek at the De-
and was called von Willebrand factor. It binds to collagen at sites of vascular in- partment of Hematology, Erasmus Uni-
jury, mediates platelet adhesion and aggregation, and serves as a carrier protein versity Medical Center, Rm. Na-820, P.O.
for coagulation factor VIII (Fig. 1).3 Von Willebrand factor also has other functions Box 2040, 3000 CA Rotterdam, the Nether-
lands, or at f.leebeek@erasmusmc.nl.
and may be involved in such processes as inflammation and angiogenesis.4
Von Willebrand’s disease is the most common inherited bleeding disorder and N Engl J Med 2016;375:2067-80.
DOI: 10.1056/NEJMra1601561
has an autosomal inheritance pattern. The disease is characterized mainly by Copyright © 2016 Massachusetts Medical Society.
mucosa-associated bleeding and bleeding after surgery and trauma. The diagnosis
is based on a personal or family history of bleeding and laboratory evidence of
abnormalities in von Willebrand factor, factor VIII, or both. Affected patients have
reduced levels of functional von Willebrand factor, and various types of von Wille
brand’s disease can be distinguished on the basis of phenotypic characteristics.
The goal of treatment is to increase von Willebrand factor levels by administering
desmopressin or by the infusion of exogenous von Willebrand factor–containing
concentrates. In this review, we discuss the latest findings regarding the patho-
physiology, diagnosis, and treatment of von Willebrand’s disease.
Cleaved Disulfide
bond
Noncovalent
bond
Collagen
receptor Active αIIbβ3
INACTIVATED
PLATELET
Inactive Uncoiled, ACTIVATED
αIIbβ3 active VWF
PLATELET
Coiled,
inactive VWF
ENDOTHELIAL CELL
Subendothelial collagen
caused by dysfunctional von Willebrand factor, cases), is the most severe form, and is caused by
resulting in a normal or reduced von Willebrand the absence of circulating von Willebrand factor.
factor antigen concentration but a large reduc- In rare cases, von Willebrand’s disease is ac-
tion in von Willebrand factor function. Type 2 is quired, rather than inherited, by means of vari-
further subdivided on the basis of specific phe- ous mechanisms that result in rapid degradation
notypic characteristics (Fig. 2). Type 3 von Will- or clearance of von Willebrand factor. The ac-
ebrand’s disease is rare (accounting for <5% of quired syndrome is not discussed here because
Monomer
Dimer
Multimer
GPIbα
Decreased Platelet Adhesion or Collagen Binding with No Loss of HMW VWF Multimers
Primary and secondary postpartum bleeding study showed that among patients with type 1
also occurs frequently.25,27,28 disease, bleeding symptoms occurred as fre-
As a result of the physiologic rise in von Wil- quently in patients who were older than 65 years
lebrand factor levels throughout life, patients of age as in those who were 18 to 65 years of
with type 1 von Willebrand’s disease may have age, which suggests that the age-dependent rise
levels within the normal range when they be- in von Willebrand factor levels does not lead to
come older.29 It is still not known whether this a mitigation of bleeding symptoms.30 Even
rise results in fewer bleeding episodes. A recent though von Willebrand factor antigen levels also
Type 3 VWD
Type 2A VWD Severe
Second-Level Tests Type 1 VWD
RIPA VWFpp
and
Normal <5 IU/dl
Multimers or reduced VWFpp
Loss of HMW ≥5 IU/dl
multimers First-Level
RIPA Tests
VWF:Ag
Enhanced <5 IU/dl
Type 2B VWD
and VWF:RCo
<30 IU/dl
Multimers
and VWF:RCo
Loss Ratio of
<30 IU/dl
of HMW Ratio of FVIII:C
multimers and to
VWF:RCo Bleeding Disorder Suspected Type 1 VWD
Ratio of VWF:Ag
to
VWF:RCo >0.6
VWF:Ag
to and
≤0.6
Multimers VWF:Ag Multimers
Normal Normal
>0.6
Type 2M VWD
Ratio of FVIII:C VWF:RCo
to 30– 50 IU/dl
VWF:Ag
≤0.6
able, although very low, von Willebrand factor In type 3 disease, both von Willebrand factor
antigen levels, who should actually be classified antigen and propeptide are absent or are present
as having severe type 1 von Willebrand’s disease, at very low levels, whereas in severe type 1 dis-
will instead be classified as having type 3 dis- ease, the antigen level is very low, but the pro-
ease. Measurement of von Willebrand factor peptide level is minimally reduced or normal
propeptide, a cleavage product formed during (Fig. 4).45
synthesis of von Willebrand factor (Fig. 1), helps When von Willebrand factor antigen is mea-
discriminate between type 3 and type 1 disease. surable, the level is considered in relation to the
results of the von Willebrand factor–ristocetin not specific enough to justify a separate classifi-
cofactor activity assay. Because of low sensitivity cation.45 Although measurement of the binding of
and precision, this assay is being replaced in an von Willebrand factor to collagen is not widely
increasing number of laboratories by new assays used in the diagnosis of von Willebrand’s dis-
measuring the binding of von Willebrand factor ease, it may have added value for identifying
to a recombinant wild-type glycoprotein Ibα cases of type 2M disease that have specific de-
fragment with the use of ristocetin or the spon- fects in collagen binding, which are usually as-
taneous binding of von Willebrand factor to a sociated with a mild bleeding phenotype.51
gain-of-function recombinant mutant glycopro- New assays that are faster and combine sev-
tein Ibα fragment.46-48 The results of these assays eral functional aspects in a single approach are
accurately reflect the platelet-binding activity of currently under development.48,52 Genotyping of
von Willebrand factor and correlate very well the VWF gene is not performed routinely in the
with results of the von Willebrand factor–risto- diagnosis of von Willebrand’s disease. In selected
cetin cofactor activity assay.48 A proportional cases of suspected von Willebrand’s disease,
decrease in von Willebrand factor antigen and however, genetic analysis may be useful for diag-
von Willebrand factor–ristocetin cofactor activity nosing type 2N and type 2B disease. In families
fits the diagnosis of type 1 von Willebrand’s with type 3 disease, genetic analysis may be use-
disease. A disproportional reduction in von Wille ful for counseling. Innovations in sequencing
brand factor–ristocetin cofactor activity as com- techniques (e.g., next-generation sequencing) have
pared with von Willebrand factor antigen (ratio made genotyping easier to perform.9
of von Willebrand factor–ristocetin cofactor activ-
ity to von Willebrand factor antigen, ≤0.6) indi- Di agnos t ic C on t rov er sie s
cates type 2 disease. Further subtyping tests,
such as assays of von Willebrand factor multimers With the use of the diagnostic algorithm shown
and ristocetin-induced platelet aggregation, are in Figure 4, the diagnosis of types 2 and 3 von
then required to determine the phenotypic char- Willebrand’s disease is quite straightforward.
acteristics that define types 2A, 2B, and 2M von However, a definitive diagnosis of type 1 disease
Willebrand’s disease (Fig. 4). is more controversial. The phenotypic character-
Factor VIII activity is also measured as a first- istic of type 1 disease is a partial reduction in
line test because the level is frequently reduced in the level of intrinsically normal von Willebrand
any type of von Willebrand’s disease.20 A reduc- factor, but it is difficult to determine an unam-
tion in factor VIII activity that is greater than the biguous cutoff level for von Willebrand factor.
reduction in von Willebrand factor antigen (ratio The lower the level, the more consistent the
of factor VIII activity to von Willebrand factor bleeding phenotype, the inheritance pattern, and
antigen, ≤0.6) may indicate type 2N von Wille- the identification of VWF mutations.35,37 Levels of
brand’s disease, which should be confirmed by von Willebrand factor–ristocetin cofactor activity
measuring the binding of factor VIII to von Wille below 30 IU per deciliter are considered to be
brand factor in order to rule out mild hemo- diagnostic of von Willebrand’s disease. Accord-
philia A.49 ing to several current guidelines, persons with a
The von Willebrand factor propeptide assay is bleeding tendency who have von Willebrand fac-
not part of the official disease classification,11 tor levels between 30 and 50 IU per deciliter (the
but it may identify von Willebrand factor variants lower limit of the normal range) are classified as
that have increased clearance, on the basis of having “low von Willebrand factor” or “possible
an increased ratio of propeptide to antigen.45,50 type 1 disease” but are not classified as having
Some authors have proposed that an increase in definitive von Willebrand’s disease, although they
the ratio of von Willebrand factor propeptide to may require treatment before undergoing sur-
antigen warrants the designation of a specific gery or in the event of a bleeding episode. Some
subtype of type 1 von Willebrand’s disease, char- persons may actually have mutations in VWF,
acterized by increased clearance of von Wille- whereas in other persons, the von Willebrand
brand factor (type 1C).50 However, enhanced clear- factor level may be determined by other genetic
ance is a characteristic of several subtypes of von loci, such as the ABO blood group.37 A low von
Willebrand’s disease, and this feature is probably Willebrand factor level can be considered a bio-
marker for an increased risk of bleeding.53 It is patients with type 2 von Willebrand’s disease,
also possible that other hemostatic defects, such desmopressin can be given intravenously (0.3 μg
as mild platelet-function disorders, contribute to per kilogram of body weight), intranasally (300 μg
the bleeding phenotype in these patients.54 [150 μg per nostril] or, in a patient with a body
A further diagnostic dilemma is posed by the weight of <50 kg, only one dose of 150 μg), or
physiologic increase in von Willebrand factor subcutaneously (0.3 μg per kilogram) to increase
levels with age throughout life. This may have an factor VIII and von Willebrand factor levels by
effect on the diagnosis of von Willebrand’s dis- two to four times. The use of a capped desmo-
ease. In childhood, the physiologically lower pressin dose of 15 or 20 μg (administered intra-
levels may be erroneously interpreted as indica- venously or subcutaneously) has been suggested,
tive of von Willebrand’s disease. Elderly patients but this approach requires further study before
who met the diagnostic criteria when they were it can be recommended.55,56 The desmopressin
younger may no longer have a von Willebrand dose can be repeated after 12 to 24 hours, de-
factor level below the lower limit of the refer- pending on the individual response. Desmopres-
ence range but may still appear to be at risk for sin is considered to be safe but may have mild
bleeding.29,30 side effects such as hypotension and flushing.
More severe, rare side effects are cardiovascular
complications and hyponatremia. The latter can
T r e atmen t
be prevented by limiting fluid intake to 1500 ml
Treatment of von Willebrand’s disease is based for 24 hours after the administration of desmo-
on normalizing von Willebrand factor and factor pressin.56,57 Various factors influence the response
VIII levels in case of bleeding or before an inter- to desmopressin, including the genotype and
vention. This can be achieved by increasing the phenotype of von Willebrand’s disease.58 There-
endogenous factor levels with the use of desmo- fore, a test-dose infusion is recommended to
pressin or by infusing exogenous coagulation establish the magnitude and duration of the re-
factors in the form of a high-purity von Wille- sponse to desmopressin.
brand factor concentrate or a low-purity factor
VIII–von Willebrand factor concentrate (Table 1). Factor Concentrate
In patients with type 3 von Willebrand’s disease
Desmopressin and in most patients with type 2 disease, von
For most patients who have type 1 von Wille- Willebrand factor–containing concentrate is the
brand’s disease or who are classified as having a treatment of choice. Plasma-derived concentrates
low level of von Willebrand factor or possible of factor VIII and von Willebrand factor are com-
type 1 von Willebrand’s disease, and for some mercially available in various ratios.59 Therefore,
Table 2. Indications for and Doses of Factor Concentrate in von Willebrand’s Disease.
Indication for VWF–Factor Target Levels for VWF–Ristocetin Cofactor Activity Duration of
VIII or VWF Concentrate* Dose† and Factor VIII Activity‡ Treatment
* VWF–factor VIII or VWF concentrate is administered in patients with type 3 disease and in patients with type 1 or 2 dis-
ease who do not have a response to desmopressin or in whom it is contraindicated.
† The dose of factor concentrate depends on the type of concentrate used. If VWF–factor VIII concentrate is used, the dose
of factor concentrate also depends on the brand of concentrate. The dose is based on an anticipated in vivo recovery
(2 IU per deciliter for every unit of factor VIII activity infused per kilogram of body weight and 1.5 IU per deciliter for
every unit of VWF–ristocetin cofactor activity infused per kilogram) and the target levels of both VWF–ristocetin cofactor
activity and factor VIII activity. If high-purity or recombinant VWF concentrate is administered, a single dose of factor
VIII concentrate should also be administered in order to achieve the target level of factor VIII immediately.
‡ Factor VIII activity, and preferably also VWF–ristocetin cofactor activity, should be monitored regularly in all patients
undergoing surgical procedures and all patients with severe bleeding episodes. If measurement of VWF–ristocetin co-
factor activity is not immediately available at a local laboratory, dosing should be based on factor VIII activity levels.
Willebrand factor concentrate has been developed. brand’s disease. In women with type 2 disease,
A phase 1 trial showed that it has increased the level of von Willebrand factor antigen also
specific activity, as compared with plasma-derived rises; however, von Willebrand factor activity
von Willebrand factor.63 Infusion of recombinant remains reduced as a result of the functional
von Willebrand factor together with a single dose defect of the protein.71 To prevent postpartum
of recombinant factor VIII was shown to have hemorrhage, women are treated with factor con-
high efficacy as a treatment to stop bleeding, centrates during labor if factor VIII or von Wille
without significant side effects, in patients with brand factor levels are less than 50 IU per deci-
severe von Willebrand’s disease.64 In 2015, recom- liter in the third trimester of pregnancy. In such
binant von Willebrand factor was approved in cases, the goal of replacement therapy is levels
the United States by the Food and Drug Admin- of von Willebrand factor and factor VIII that are
istration for the treatment of bleeding episodes higher than 100 IU per deciliter at the time of
in adults with von Willebrand’s disease. delivery, ensuring trough levels of more than 50 IU
per deciliter. In patients with type 1 disease who
Prophylactic Treatment do not have sufficiently high factor VIII or von
In contrast to patients with hemophilia, regular Willebrand factor levels despite the physiologic
infusion of factor concentrate to prevent bleed- rise in values during pregnancy, desmopressin
ing is not commonly used in patients with von can be administered, preferably after clamping of
Willebrand’s disease, although beneficial results the umbilical cord. Tranexamic acid can be safely
have been observed in several case series.65,66 administered in the postpartum period. Despite
Recently, a prospective dose-escalating study these measures, women with von Willebrand’s
evaluated prophylaxis in patients who had a severe disease have more postpartum bleeding than
bleeding phenotype of von Willebrand’s disease.67 women without von Willebrand’s disease.27,28,71
Although only 11 patients were included in this
study, which was stopped because of slow en- Additional Treatment
rollment, a significant reduction in the number Fibrinolysis inhibitors, such as tranexamic acid
of bleeding episodes, including gastrointestinal and aminocaproic acid, are important as addi-
bleeding, joint bleeding, and severe epistaxis, was tional treatment of mucocutaneous bleeding.
observed in patients receiving regular prophy- They can also be used to reduce bleeding and
laxis. Most of the patients were treated with 50 especially to prevent rebleeding in patients under-
IU of von Willebrand factor–ristocetin cofactor going surgical or dental interventions, although
activity per kilogram two or three times a week. evidence from randomized trials is lacking.72
Besides systemic treatment for bleeding or sur-
Treatment of Gynecologic Bleeding gery, local measures, such as use of tranexamic
In women with von Willebrand’s disease who acid mouthwash or additional suturing, may be
have menorrhagia, gynecologic and hormonal required. Protracted bleeding despite treatment
abnormalities should be ruled out. Once they with von Willebrand factor concentrate can some-
have been ruled out, treatment should be initi- times be managed by platelet transfusion be-
ated with oral contraceptives containing both cause von Willebrand factor is present within the
progestin and estrogen. In addition, antifibrino- transfused platelets.61 An innovative treatment
lytic treatment with tranexamic acid may reduce strategy is daily subcutaneous administration of
menstrual blood loss.68 A levonorgestrel-releasing interleukin-11, which increases von Willebrand
intrauterine device can be placed in patients who factor and factor VIII levels by a factor of 1.3 to
do not have a response to oral contraceptives.69 2.0, presumably by increasing von Willebrand
Even more severe cases may benefit from desmo- factor messenger RNA levels in patients with
pressin or von Willebrand factor concentrate.68 If type 1 von Willebrand’s disease that is unrespon-
these approaches are not successful, endometrial sive to treatment with desmopressin.73 One trial
ablation or hysterectomy can be performed.70 showed that interleukin-11 reduced the severity
In healthy pregnant women, factor VIII and of bleeding in women with menorrhagia.74 Angio-
von Willebrand factor levels increase by a factor of dysplasia-associated gastrointestinal bleeding epi-
2 to 3 at the time of labor, and these increases sodes are frequently severe and not responsive to
are also seen in women with type 1 von Wille- treatment with von Willebrand factor concentrate.
Antiangiogenic drugs may be beneficial in such Prospective studies are needed to address the
cases. Several case reports have described the question of whether persons who have low von
successful use of atorvastatin and thalidomide.18,75 Willebrand factor levels and a bleeding tendency
Interleukin-11, atorvastatin, and thalidomide have but do not meet the diagnostic criteria for von
not yet been approved for use in von Willebrand’s Willebrand’s disease benefit from hemostatic
disease. treatment during surgical interventions. Similar
studies are needed to determine whether treat-
ment is warranted for elderly patients with von
F u t ur e Per spec t i v e s
Willebrand’s disease in whom von Willebrand
In the past decade, new pathophysiological in- factor has risen to levels within the normal range.
sights into von Willebrand’s disease and im- Dr. Leebeek reports receiving consulting fees from UniQure
proved diagnostic approaches and treatment and Baxalta (Shire) and grant support from CSL Behring and
Baxter, all paid to his institution, and lecture fees and travel
options have emerged. Diagnosis will be further support from Roche; and Dr. Eikenboom, receiving lecture fees
improved by the introduction of more reproduc- from Roche and grant support from CSL Behring, all paid to his
ible and rapid assays of von Willebrand factor institution. No other potential conflict of interest relevant to
this article was reported.
function. Next-generation sequencing will facili- Disclosure forms provided by the authors are available with
tate the routine identification of mutations in the full text of this article at NEJM.org.
VWF. More widespread use of prophylactic treat- We thank Wichor M. Bramer, biomedical information spe-
cialist at Erasmus University Medical Center, for assistance with
ment for severely affected patients seems war- the literature search (see the Supplementary Appendix, available
ranted, considering the reported beneficial effects. with the full text of this article at NEJM.org).
References
1. Von Willebrand E. Hereditar pseudo- et al. Molecular and clinical profile of von giodysplastic gastrointestinal bleeding
hemofili. Fin Lakaresallsk Handl 1926;68: Willebrand disease in Spain (PCM-EVW-ES): in von Willebrand disease. Haemophilia
87-112. proposal for a new diagnostic paradigm. 2015;21:338-42.
2. Springer TA. Von Willebrand factor, Thromb Haemost 2016;115:40-50. 19. van Galen KPM, Mauser-Bunschoten
Jedi knight of the bloodstream. Blood 2014; 10. Castaman G, Goodeve A, Eikenboom J. EP, Leebeek FWG. Hemophilic arthropa-
124:1412-25. Principles of care for the diagnosis and thy in patients with von Willebrand dis-
3. Zimmerman TS, Ratnoff OD, Powell treatment of von Willebrand disease. ease. Blood Rev 2012;26:261-6.
AE. Immunologic differentiation of classic Haematologica 2013;98:667-74. 20. Federici AB, Bucciarelli P, Castaman
hemophilia (factor 8 deficiency) and von 11. Sadler JE, Budde U, Eikenboom JC, et al. G, et al. The bleeding score predicts clini-
Willebrand’s disease, with observations Update on the pathophysiology and classifi- cal outcomes and replacement therapy in
on combined deficiencies of antihemo- cation of von Willebrand disease: a report adults with von Willebrand disease. Blood
philic factor and proaccelerin (factor V) of the Subcommittee on von Willebrand 2014;123:4037-44.
and on an acquired circulating anticoagu- Factor. J Thromb Haemost 2006;4:2103-14. 21. de Wee EM, Mauser-Bunschoten EP,
lant against antihemophilic factor. J Clin 12. Cuker A, Connors JM, Katz JT, Levy Van Der Bom JG, et al. Health-related
Invest 1971;50:244-54. BD, Loscalzo J. A bloody mystery. N Engl quality of life among adult patients with
4. Lenting PJ, Casari C, Christophe OD, J Med 2009;361:1887-94. moderate and severe von Willebrand dis-
Denis CV. von Willebrand factor: the old, 13. Sanders YV, Fijnvandraat K, Boender J, ease. J Thromb Haemost 2010;8:1492-9.
the new and the unknown. J Thromb Hae- et al. Bleeding spectrum in children with 22. Kadir RA, Edlund M, Von Mackensen
most 2012;10:2428-37. moderate or severe von Willebrand dis- S. The impact of menstrual disorders on
5. Nichols WL, Hultin MB, James AH, ease: relevance of pediatric-specific bleed- quality of life in women with inherited
et al. Von Willebrand disease (VWD): evi- ing. Am J Hematol 2015;90:1142-8. bleeding disorders. Haemophilia 2010;16:
dence-based diagnosis and management 14. de Wee EM, Sanders YV, Mauser-Bun- 832-9.
guidelines, the National Heart, Lung, and schoten EP, et al. Determinants of bleed- 23. Kadir RA, Economides DL, Sabin CA,
Blood Institute (NHLBI) Expert Panel re- ing phenotype in adult patients with mod- Owens D, Lee CA. Frequency of inherited
port (USA). Haemophilia 2008;14:171-232. erate or severe von Willebrand disease. bleeding disorders in women with menor-
6. Rodeghiero F, Castaman G, Dini E. Thromb Haemost 2012;108:683-92. rhagia. Lancet 1998;351:485-9.
Epidemiological investigation of the prev- 15. Silwer J. Von Willebrand’s disease in 24. Miller CH, Philipp CS, Stein SF, et al.
alence of von Willebrand’s disease. Blood Sweden. Acta Paediatr Scand Suppl 1973; The spectrum of haemostatic characteris-
1987;69:454-9. 238:1-159. tics of women with unexplained menor-
7. Sadler JE, Mannucci PM, Berntorp E, 16. Sanders YV, de Wee EM, Meijer K, et al. rhagia. Haemophilia 2011;17(1):e223-9.
et al. Impact, diagnosis and treatment of Von Willebrand disease in the Nether- 25. De Wee EM, Knol HM, Mauser-Bun-
von Willebrand disease. Thromb Haemost lands: the WiN study. Ned Tijdschr schoten EP, et al. Gynaecological and ob-
2000;84:160-74. Geneeskd 2014;158:A6518. (In Dutch.) stetric bleeding in moderate and severe
8. Laffan MA, Lester W, O’Donnell JS, et 17. Veyradier A, Boisseau P, Fressinaud E, von Willebrand disease. Thromb Haemost
al. The diagnosis and management of von et al. A laboratory phenotype/genotype 2011;106:885-92.
Willebrand disease: a United Kingdom correlation of 1167 French patients from 26. James AH. More than menorrhagia:
Haemophilia Centre Doctors Organization 670 families with von Willebrand disease: a review of the obstetric and gynaeco-
guideline approved by the British Com- a new epidemiologic picture. Medicine logical manifestations of von Willebrand
mittee for Standards in Haematology. Br J (Baltimore) 2016;95(11):e3038. disease. Thromb Res 2007;120:Suppl 1:
Haematol 2014;167:453-65. 18. Makris M, Federici AB, Mannucci PM, S17-20.
9. Batlle J, Pérez-Rodríguez A, Corrales I, et al. The natural history of occult or an- 27. Stoof SCM, van Steenbergen HW,
Zwagemaker A, et al. Primary postpartum factor and contributes to the variation in 54. Gudmundsdottir BR, Marder VJ, Onun-
haemorrhage in women with von Wille- plasma von Willebrand factor levels. Blood darson PT. Risk of excessive bleeding
brand disease or carriership of haemo- 2013;121:5228-37. associated with marginally low von Wille
philia despite specialised care: a retro- 41. Sanders YV, van der Bom JG, Isaacs A, brand factor and mild platelet dysfunc-
spective survey. Haemophilia 2015; 21: et al. CLEC4M and STXBP5 gene varia- tion. J Thromb Haemost 2007;5:274-81.
505-12. tions contribute to von Willebrand factor 55. Siew DA, Mangel J, Laudenbach L,
28. Kouides PA. An update on the man- level variation in von Willebrand disease. Schembri S, Minuk L. Desmopressin re-
agement of bleeding disorders during J Thromb Haemost 2015;13:956-66. sponsiveness at a capped dose of 15 μg in
pregnancy. Curr Opin Hematol 2015;22: 42. Tosetto A, Rodeghiero F, Castaman G, type 1 von Willebrand disease and mild
397-405. et al. A quantitative analysis of bleeding hemophilia A. Blood Coagul Fibrinolysis
29. Rydz N, Grabell J, Lillicrap D, James symptoms in type 1 von Willebrand dis- 2014;25:820-3.
PD. Changes in von Willebrand factor ease: results from a multicenter European 56. Leissinger C, Carcao M, Gill JC, Jour-
level and von Willebrand activity with age study (MCMDM-1 VWD). J Thromb Hae- neycake J, Singleton T, Valentino L. Desmo-
in type 1 von Willebrand disease. Haemo- most 2006;4:766-73. pressin (DDAVP) in the management of
philia 2015;21:636-41. 43. Rodeghiero F, Tosetto A, Abshire T, patients with congenital bleeding disor-
30. Sanders YV, Giezenaar MA, Laros-van et al. ISTH/SSC bleeding assessment tool: ders. Haemophilia 2014;20:158-67.
Gorkom BAP, et al. Von Willebrand dis- a standardized questionnaire and a pro- 57. Stoof SCM, Cnossen MH, de Maat
ease and aging: an evolving phenotype. posal for a new bleeding score for inher- MPM, Leebeek FWG, Kruip MJHA. Side
J Thromb Haemost 2014;12:1066-75. ited bleeding disorders. J Thromb Hae- effects of desmopressin in patients with
31. Sanders YV, Eikenboom J, de Wee EM, most 2010;8:2063-5. bleeding disorders. Haemophilia 2016;22:
et al. Reduced prevalence of arterial 44. Elbatarny M, Mollah S, Grabell J, et al. 39-45.
thrombosis in von Willebrand disease. Normal range of bleeding scores for the 58. Castaman G, Lethagen S, Federici AB,
J Thromb Haemost 2013;11:845-54. ISTH-BAT: adult and pediatric data from et al. Response to desmopressin is influ-
32. Seaman CD, Yabes J, Comer DM, Ragni the Merging Project. Haemophilia 2014; enced by the genotype and phenotype in
MV. Does deficiency of von Willebrand 20:831-5. type 1 von Willebrand disease (VWD): re-
factor protect against cardiovascular dis- 45. Sanders YV, Groeneveld D, Meijer K, sults from the European Study MCMDM-
ease? Analysis of a national discharge et al. Von Willebrand factor propeptide 1VWD. Blood 2008;111:3531-9.
register. J Thromb Haemost 2015; 13: and the phenotypic classification of von 59. Lethagen S, Carlson M, Hillarp A.
1999-2003. Willebrand disease. Blood 2015;125:3006- A comparative in vitro evaluation of six
33. Hampshire DJ, Goodeve AC. The Inter- 13. von Willebrand factor concentrates. Hae-
national Society on Thrombosis and Hae- 46. Stufano F, Lawrie AS, La Marca S, Ber- mophilia 2004;10:243-9.
matosis von Willebrand Disease Database: benni C, Baronciani L, Peyvandi F. A two- 60. Borel-Derlon A, Federici AB, Roussel-
an update. Semin Thromb Hemost 2011; centre comparative evaluation of new au- Robert V, et al. Treatment of severe von
37:470-9. tomated assays for von Willebrand factor Willebrand disease with a high-purity von
34. Bowman M, Tuttle A, Notley C, et al. ristocetin cofactor activity and antigen. Willebrand factor concentrate (Wilfactin):
The genetics of Canadian type 3 von Wil- Haemophilia 2014;20:147-53. a prospective study of 50 patients. J Thromb
lebrand disease: further evidence for co- 47. Flood VH, Gill JC, Morateck PA, et al. Haemost 2007;5:1115-24.
dominant inheritance of mutant alleles. Gain-of-function GPIb ELISA assay for 61. Mannucci PM. Treatment of von Wille
J Thromb Haemost 2013;11:512-20. VWF activity in the Zimmerman Program brand’s disease. N Engl J Med 2004;351:
35. Goodeve A, Eikenboom J, Castaman G, for the Molecular and Clinical Biology of 683-94.
et al. Phenotype and genotype of a cohort VWD. Blood 2011;117(6):e67-74. 62. Coppola A, Franchini M, Makris M,
of families historically diagnosed with 48. Bodó I, Eikenboom J, Montgomery R, Santagostino E, Di Minno G, Mannucci
type 1 von Willebrand disease in the Euro- et al. Platelet-dependent von Willebrand PM. Thrombotic adverse events to coagu-
pean study, Molecular and Clinical Mark- factor activity — nomenclature and meth- lation factor concentrates for treatment of
ers for the Diagnosis and Management of odology: communication from the SSC of patients with haemophilia and von Wille-
Type 1 von Willebrand Disease (MCMDM- the ISTH. J Thromb Haemost 2015; 13: brand disease: a systematic review of pro-
1VWD). Blood 2007;109:112-21. 1345-50. spective studies. Haemophilia 2012;18(3):
36. James PD, Notley C, Hegadorn C, et al. 49. Gupta M, Lillicrap D, Stain AM, Fried- e173-87.
The mutational spectrum of type 1 von man KD, Carcao MD. Therapeutic conse- 63. Mannucci PM, Kempton C, Millar C,
Willebrand disease: results from a Cana- quences for misdiagnosis of type 2N von et al. Pharmacokinetics and safety of a
dian cohort study. Blood 2007;109:145-54. Willebrand disease. Pediatr Blood Cancer novel recombinant human von Willebrand
37. Flood VH, Christopherson PA, Gill JC, 2011;57:1081-3. factor manufactured with a plasma-free
et al. Clinical and laboratory variability in 50. Haberichter SL, Balistreri M, Christo- method: a prospective clinical trial. Blood
a cohort of patients diagnosed with type 1 pherson P, et al. Assay of the von Wille- 2013;122:648-57.
VWD in the United States. Blood 2016; brand factor (VWF) propeptide to identify 64. Gill JC, Castaman G, Windyga J, et al.
127:2481-8. patients with type 1 von Willebrand dis- Hemostatic efficacy, safety, and pharma-
38. Jenkins PV, O’Donnell JS. ABO blood ease with decreased VWF survival. Blood cokinetics of a recombinant von Wille-
group determines plasma von Willebrand 2006;108:3344-51. brand factor in severe von Willebrand
factor levels: a biologic function after all? 51. Favaloro EJ. Evaluation of commercial disease. Blood 2015;126:2038-46.
Transfusion 2006;46:1836-44. von Willebrand factor collagen binding 65. Berntorp E, Petrini P. Long-term pro-
39. Smith NL, Chen MH, Dehghan A, et al. assays to assist the discrimination of phylaxis in von Willebrand disease. Blood
Novel associations of multiple genetic loci types 1 and 2 von Willebrand disease. Coagul Fibrinolysis 2005;16:Suppl 1:S23-6.
with plasma levels of factor VII, factor VIII, Thromb Haemost 2010;104:1009-21. 66. Abshire T. The role of prophylaxis in
and von Willebrand factor: the CHARGE 52. Roberts JC, Morateck PA, Christo- the management of von Willebrand dis-
(Cohorts for Heart and Aging Research in pherson PA, et al. Rapid discrimination of ease: today and tomorrow. Thromb Res
Genome Epidemiology) Consortium. Cir- the phenotypic variants of von Willebrand 2009;124:Suppl 1:S15-9.
culation 2010;121:1382-92. disease. Blood 2016;127:2472-80. 67. Abshire T, Cox-Gill J, Kempton CL,
40. Rydz N, Swystun LL, Notley C, et al. 53. Sadler JE. Von Willebrand disease et al. Prophylaxis escalation in severe von
The C-type lectin receptor CLEC4M binds, type 1: a diagnosis in search of a disease. Willebrand disease: a prospective study
internalizes, and clears von Willebrand Blood 2003;101:2089-93. from the von Willebrand Disease Prophy-
laxis Network. J Thromb Haemost 2015; a survey and literature review. Haemophilia binant interleukin-11 in desmopressin-
13:1585-9. 2016;22:397-402. unresponsive von Willebrand disease and
68. Kouides PA, Byams VR, Philipp CS, 71. James AH, Konkle BA, Kouides P, et al. mild or moderate haemophilia A. Thromb
et al. Multisite management study of Postpartum von Willebrand factor levels Haemost 2013;109:248-54.
menorrhagia with abnormal laboratory in women with and without von Wille- 74. Ragni MV, Jankowitz RC, Jaworski K,
haemostasis: a prospective crossover study brand disease and implications for pro- Merricks EP, Kloos MT, Nichols TC. Phase
of intranasal desmopressin and oral phylaxis. Haemophilia 2015;21:81-7. II prospective open-label trial of recombi-
tranexamic acid. Br J Haematol 2009;145: 72. van Galen KP, Engelen ET, Mauser- nant interleukin-11 in women with mild
212-20. Bunschoten EP, van Es RJ, Schutgens RE. von Willebrand disease and refractory men-
69. Chi C, Huq FY, Kadir RA. Levonor Antifibrinolytic therapy for preventing oral orrhagia. Thromb Haemost 2011;106:641-5.
gestrel-releasing intrauterine system for bleeding in patients with haemophilia or 75. Engelen ET, van Galen KP, Schutgens
the management of heavy menstrual von Willebrand disease undergoing minor RE. Thalidomide for treatment of gastro-
bleeding in women with inherited bleed- oral surgery or dental extractions. Cochrane intestinal bleedings due to angiodysplasia:
ing disorders: long-term follow-up. Con- Database Syst Rev 2015;12:CD011385. a case report in acquired von Willebrand
traception 2011;83:242-7. 73. Ragni MV, Novelli EM, Murshed A, syndrome and review of the literature.
70. Ragni MV, Machin N, Malec LM, et al. Merricks EP, Kloos MT, Nichols TC. Phase Haemophilia 2015;21:419-29.
Von Willebrand factor for menorrhagia: II prospective open-label trial of recom- Copyright © 2016 Massachusetts Medical Society.